
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Cabaletta Bio Inc (CABA)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CABA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $12.25
1 Year Target Price $12.25
8 | Strong Buy |
2 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.07% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 263.42M USD | Price to earnings Ratio - | 1Y Target Price 12.25 |
Price to earnings Ratio - | 1Y Target Price 12.25 | ||
Volume (30-day avg) 12 | Beta 3.01 | 52 Weeks Range 0.99 - 5.46 | Updated Date 10/16/2025 |
52 Weeks Range 0.99 - 5.46 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.39% | Return on Equity (TTM) -76.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61618039 | Price to Sales(TTM) - |
Enterprise Value 61618039 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.44 | Shares Outstanding 91465233 | Shares Floating 61644823 |
Shares Outstanding 91465233 | Shares Floating 61644823 | ||
Percent Insiders 1.65 | Percent Institutions 79.77 |
Upturn AI SWOT
Cabaletta Bio Inc

Company Overview
History and Background
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Founded in 2017, the company aims to develop targeted and selective therapies that can eliminate the underlying cause of these diseases.
Core Business Areas
- Cell Therapy Development: Cabaletta Bio is focused on the development of targeted cell therapies, specifically Chimeric AutoAntibody Receptor (CAAR) T cells, designed to selectively eliminate pathogenic B cells.
- Research and Discovery: The company is also engaged in ongoing research and discovery efforts to identify new targets and develop novel CAAR T-cell therapies for a range of autoimmune diseases.
- Clinical Trials: Cabaletta Bio focuses on bringing CAAR-T cell therapies through clinical trials to demonstrate safety and efficacy.
Leadership and Structure
Steven Nichtberger, M.D. serves as the Chief Executive Officer. The company has a board of directors and a management team with expertise in cell therapy, immunology, and drug development.
Top Products and Market Share
Key Offerings
- Descartes-25: Descartes-25 (CD19-CAAR-T) is Cabaletta Biou2019s lead product candidate for the treatment of MuSK-associated myasthenia gravis (MG). No market share yet due to development stage. Competitors include pharmaceutical companies developing immunosuppressant drugs and other biologics for MG, such as argenx (ARGX) with Vyvgart.
- Descartes-30: Descartes-30 (DSG3-CAAR-T) is being developed for the treatment of desmoglein 3 (DSG3)-positive pemphigus vulgaris (PV). No market share yet due to development stage. Competitors include pharmaceutical companies developing immunosuppressant drugs and biologics for PV, such as Roche (RHHBY) with Rituxan.
Market Dynamics
Industry Overview
The autoimmune disease market is a large and growing market with significant unmet medical needs. There is increasing interest in cell-based therapies and precision medicine approaches.
Positioning
Cabaletta Bio is positioned as a leader in the development of CAAR T-cell therapies for B cell-mediated autoimmune diseases. Its competitive advantage lies in its proprietary CAAR T-cell technology platform and its focus on highly specific targeting of pathogenic B cells.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is substantial, estimated at tens of billions of dollars annually. Cabaletta Bio is positioned to address a subset of this market with its targeted cell therapies. The exact TAM specific to CAAR-T cell therapy is still evolving with clinical development and market acceptance. Cabaletta's strategy of targeting specific B-cell mediated autoimmune disorders allows them to focus their resources on areas of high unmet need.
Upturn SWOT Analysis
Strengths
- Proprietary CAAR T-cell technology platform
- Focus on highly specific targeting of pathogenic B cells
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Clinical-stage company with no approved products
- High risk associated with novel cell therapy development
- Reliance on successful clinical trial outcomes
- High cash burn rate
Opportunities
- Expansion of CAAR T-cell technology to other autoimmune diseases
- Potential for partnerships and collaborations
- Breakthrough Therapy Designation and other regulatory incentives
- Addressing unmet medical needs in specific autoimmune disorders
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles and evolving guidelines
- Manufacturing challenges and scalability
Competitors and Market Share
Key Competitors
- ARGX
- RHHBY
- JNJ
- BMY
Competitive Landscape
Cabaletta Bio competes with established pharmaceutical companies and other biotechnology companies developing therapies for autoimmune diseases. Cabaletta's CAAR T-cell approach offers the potential for targeted and selective treatment, but faces challenges related to manufacturing and scalability compared to conventional drugs.
Growth Trajectory and Initiatives
Historical Growth: Cabaletta Bio's historical growth is characterized by the advancement of its CAAR T-cell therapy platform and the progress of its clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of its products. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Descartes-25 and Descartes-30, as well as efforts to expand the CAAR T-cell platform to other autoimmune diseases.
Summary
Cabaletta Bio is a clinical-stage company with a promising CAAR T-cell technology platform targeting B cell-mediated autoimmune diseases. They have yet to bring a drug to market and their success depends on positive clinical trial outcomes. Key strengths include their innovative approach, but weaknesses include clinical trial risk and high cash burn. Potential threats are competition and regulatory hurdles. A solid cash position allows them to proceed with ongoing clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cabaletta Bio Inc. SEC Filings
- Cabaletta Bio Inc. Investor Relations
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. All financial data is in USD unless otherwise stated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cabaletta Bio Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2019-10-25 | Co-Founder, Chairman, CEO & President Dr. Steven A. Nichtberger M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 167 | Website https://www.cabalettabio.com |
Full time employees 167 | Website https://www.cabalettabio.com |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.